1	IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSASISTRICT COURT TOPEKA, KANSAS
2	TOPEKA, KANSAS
3	2003 APR - 1 P 1: 16
4	UNITED STATES OF AMERICA,) RAUTHL DELOACH
5) AT TOPEKA DEPUTY.
6) 00-40104-01/02
7	WILLIAM L. PICKARD and) CLYDE APPERSON,) Defendants.)
8	PARTIAL TRANSCRIPT CONSISTING OF THE ENTIRE
9	TESTIMONY OF DEA CHEMIST ROGER ELY HAD DURING JURY TRIAL
10	BEFORE HONORABLE RICHARD D. ROGERS
11	and a jury of 12
12	on March 11, 2003
13	APPEARANCES:
14	For the Plaintiff: Mr. Gregory G. Hough Asst. U.S. Attorney
15	290 Federal Building 444 Quincy Street
16	Topeka, Kansas 66683
17	For the Defendant: Mr. William Rork (Pickard) Rork Law Office
18	1321 SW Topeka Blvd. Topeka, Kansas 66612
19	For the Defendant: Mr. Mark Bennett
20	(Apperson) Bennett, Hendrix & Moylan
21	5605 SW Barrington Court S Topeka, Kansas 66614
22	Court Reporter: Kelli Stewart, RPR, CRR, RMR
23	Nora Lyon & Associates 1515 South Topeka Avenue Topoka Kansas 66612
24	Topeka, Kansas 66612
25	
	l l

NORA LYON & ASSOCIATES, INC. 1515 S.W. Topeka Blvd., Topeka, KS 66612 Phone: (785) 232-2545 FAX: (785) 232-2720

1 MR. RORK: Your Honor, the defense 2 would call Roger Ely. 3 4 ROGER ELY, 5 called as a witness on behalf of the Defendant 6 Pickard, was sworn, and testified as follows: 7 8 MR. RORK: And then, Your Honor, just 9 for the record, I would note that there would 10 be a matter I would need to take up with you. Instead of doing it at this time, I would ask 11 to do it out of order when I get done 12 13 questioning the witness at the next break. 14 THE COURT: That would be fine. 15 MR. RORK: Thank you. 16 DIRECT EXAMINATION BY MR. RORK: 17 Would you state your name for the record, 18 0. 19 please? 20 Yes. It's Roger Ely, E-L-Y. Α. 21 And, Mr. Ely, how are you employed? Q. 22 Α. I'm a senior forensic chemist with the Drug 23 Enforcement Administration's laboratory in San 24 Francisco, California. 25 And how long have you been employed in that Q.

1 capacity? 2 Α. It will be 16 years this August. 3 And what is your training and background in as Q. a senior forensic agent? 4 5 Senior forensic chemist. Α. 6 Q. Sorry. 7 Α. I have a bachelor's degree in chemistry. 8 Judge, we'll stipulate MR. HOUGH: 9 that he is a senior forensic chemist 10 qualified--11 THE COURT: Well, he'll probably want 12 to give -- overruled. I mean, go ahead. 13 (BY MR. RORK) You may respond. Q. 14 I have a bachelor's degree in chemistry from Α. 15 California State University in Fresno. At the 16 time I was pursuing my degree, I worked in the 17 crime laboratory at the Fresno County Sheriff's 18 Department. 19 In 1982, I went to work for the 20 Washington State Patrol Crime Laboratory system 21 located in a satellite laboratory in Kelso, 22 Washington, which is about 40 miles north of 23 Portland, Oregon. 24 And how long were you in that position in 0. 25 Portland, Oregon, until you then went to San

Francisco?

1

2

3

4

5

6

7

8

9

10

11

12

18

19

20

21

22

23

24

- A. I was about -- let's see seventy -- about six-and-a-half years at the Fresno County position and about five-and-a-half years with the Washington State Patrol.
- Q. And what do your duties involve?
- A. My primary duty is the examination of what we call solid dosage drugs. Those are items which are seized by our agents and other federal agencies for the presence of controlled substances.
- Q. And how is that undertaken in general?
- 13 A. Using chemistry.
- 14 | O. Yes. In an office somewhere?
- 15 A. In a laboratory in San Francisco.
- Q. What are your professional organizations that you belong to?
 - A. I am a member of the Northwest Association of
 Forensic Scientists. I'm also a member and one
 of the founders of a group called the
 Clandestine Laboratory Investigating Chemists
 Association.
 - Q. Is that also known by the initials CLIC?
 - A. Yes, we refer to it as CLIC.
 - Q. And go on with your other associations and I'll

get back to that one.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- A. That's pretty much it for now.
- Q. With respect to the-- the Association of Forensic Scientists what does that involve?
- A. With the Northwest Association of Forensic Scientists, I was a general member joining about 1982. I have held offices as the newsletter editor for about seven or eight years. I was also membership secretary for about six or seven years. I was active in the association in rewriting and updating our by-laws and constitution.

I have presented technical papers at their meetings, I have provided training sessions in the areas of clandestine drug laboratory investigation and also crime scene investigative photography for their CLIA sessions.

- Q. And with respect to your-- you said you were a founding member of CLIC?
- A. Yes, sir.
- Q. And what was the purpose for that organization?
- A. The purpose of the organization--
- 24 | O. Yes.
- 25 A. -- was in 1988, '89, a couple of us who do a

lot of drug laboratory work, especially for methamphetamine laboratories, saw a need to have an information-sharing vehicle. We proposed that we would try to start a forensic association dealing specifically with clandestine drug laboratory information and seizures, as that there was nothing like that existing in the world at the time.

- Q. And in starting that up, who was allowed to be a member of that?
- A. Only individuals who worked for law enforcement agencies who actively were involved in the investigation or-- of the scene and also the analysis of suspected methamphetamine laboratories, police officers who had investigative duties with clandestine laboratories, supervisors who might supervise a chemist or an investigator to-- in doing such duties. And then we have another category that if we felt that the individuals had a need to know or would benefit the membership, then we would also allow them to join.
- Q. And with respect to someone that had a need to know, was there a membership application that was submitted or how did that come about?

A. Yes, there was a membership application. If you wanted to fall under that particular category, you had to provide a written justification. At the time of the justification, it would go to the membership committee and usually to the Board of Directors for a decision.

We would look at impact, we would look at things such as risks of what we considered sensitive information in the use of that particular information, the likelihood that it might get into the hands of individuals who didn't have a right or a need to know that type of information.

- Q. And I assume, as with any organization, when you first began in the year of 1988 and '89, how much was your membership then, do you know?
- A. We established a level at 130 prospective members. We either— there were about eight of us that set up the group. We all had contacts in the field. We made notice to those individuals of our intentions to try to form a group such as CLIC. At the time we set a break—even point about 130 people—— excuse me, 100 people to go ahead with the incorporation

papers in the state of California. As it was, we had about 130 to 136 who were interested.

At our first meeting in San Diego, we took on about another 75 members. Currently we're sitting right about 500 members, representing the-- most of them are from the United States, and they also represent probably about another 15 foreign countries.

- Q. Around 1995 do you have any idea how many members you had?
- A. No, not offhand.

- Q. And would the membership that was initially set up with the 130, was that throughout the United States or limited to a geographical area?
- A. It was open throughout the United States. The biggest draw of our individuals happened to have come from California, primarily because that's where the methamphetamine laboratory was-- the problem was the worst.
- Q. And was the primary purpose initially for CLIC dealing with methamphetamine laboratories?
- A. That's primarily been the thrust of the organization, period, has been methamphetamine laboratories. We saw it not only as a way to get information out, but also to provide needed

1 training in analytical methodology and trends 2 and other types of information which would 3 better help the field chemists investigate dangerous situations of clandestine drug labs. 4 5 And what is your definition of a clandestine Q. 6 drug lab? 7 Well, my definition of a clandestine drug Α. 8 laboratory would be any laboratory 9 manufacturing a controlled substance that isn't 10 licensed by DEA within the United States. 11 And other than the DEA laboratories where you 0. 12 worked at, are there such laboratories that are 13 permitted or allowed to be licensed by the DEA 14 to manufacture substances that you're aware of? 15 I don't know that. Α. 16 Like for private labs, are there private labs 0. 17 that are authorized to identify or test 18 controlled substances? 19 Α. I'm not familiar with how the regulatory 20 control goes regarding the DEA licensing. 21 Q. When you talked about the analytical 22 methodology, what would that involve? 23 Α. That would involve the different and novel 24 methods of analyzing precursors or controlled substances, we do a lot of work to try to 25

provide what we would consider profiling information where we would take a sample and not necessarily look at the main components, say methamphetamine, but look at the stuff down in the grass, down in the baseline. And from that, try to determine what kind of route or methodology the individual was using to make the drug. That helps us establish a case based on precursors present or reagents.

There are other types of analytical methodology, for example, now are iodine and red phosphorous, a lot of these laboratories don't have elemental methods to identify these substances and people in our association have come up with alternatives using gas chromatography and mass spectroscopy, which is something that all of the labs do have.

- Q. And when you say identify precursors, are you talking about to actually analyze a substance and see what it is or-- or what do you do?
- A. Yes.

- Q. And when you talked about tracking the precursor, who does that involve?
- A. I didn't say anything about tracking the precursor.

- Q. Well, you indicated that they did something--something with the precursor. What was it?
- A. Analyze the precursor.
- Q. Right. And you talked about a controlled -- for controlled substances.
- A. Yes.

- Q. But it was a method to analyze precursors that were presented to you by someone or how do you acquire those?
- A. Most of the precursors are pretty straightforward. Some of the multi-synthetic group where you've got to go through several steps, there is not a lot of good analytical data there for us to do the identification. So people would present their findings. Some of the by-product and profiling we would do is hopefully get enough information from the finished sample that would point back to a particular route or a particular method that was used to manufacture that controlled substance.
- Q. And when you're talking about a route, does that mean like a geographical area? What do you mean by a route?
- A. A route is what chemicals were used. Chemistry

1 is one of those things where it would be like 2 driving from here to Kansas City, there are 3 numerous different roads that you can take to 4 get there. If you take the fastest way, you 5 will get there guickly. If you want to take 6 country roads, you can take country roads. 7 Eventually, you're going to get to Kansas City. 8 And that route analysis is different than as to Ο. 9 what path the precursor may have traveled to 10 arrive at the location it was used. 11 what I'm trying to say. 12 Yes, that's correct. It has nothing to do with Α. 13 the physical tracking of that material. 14 And what-- you had indicated that there was the 0. 15 iodine and red phosphorous as a precursor. And 16 what-- what to you is a definition-- what do 17 you define as a precursor? 18 What I define as a precursor is any chemical or Α. 19 substance which donates a portion of its 20 chemical structure to the final product or to 21 an intermediate along the way to the final 22 product. 23 And is the precursor identified by you in the 0. 24 testing at the laboratory of the substance 25 given to you by somebody? For instance, if

- you-- if a sample is gathered by a DEA agent
 somewhere, I assume that's who you get your
 samples from?
 - A. That's correct.
 - Q. Do you get your samples also from state agencies?
 - A. We can.
 - Q. Do you get your samples from private individuals?
- 10 A. No.

5

6

7

8

9

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. The samples that are given to you by the DEA agents, are those usually acquired by someone out on the street?
- A. I-- they come from the agents. The method and manner which they were obtained really is not of concern to me.
- Q. So when you receive the item, then, in the route and tracking that you do, again, doesn't deal with the physical manner of the item, it deals with the contents of the sample.
- A. It deals with how that particular substance was made.
- Q. And when you take the analytical approach to how that substance was made, what type of identifiers are you looking for?

A. We're looking for reaction by-products as a rule. In the manufacture of a controlled substance— or of any substance or in any type of chemistry when you run a reaction, there are very, very few reactions that exist where starting with components A and B that combine and totally make C, your final product. Most often, there are side reactions which will form other types of product. And from those other types of products, we can make an interpretation.

For example, in baking when you bake a cake, you put the cake mix together, in the end you get a cake. With chemistry, when you put a cake together, you'll end up with a cake, you may end up with a couple of cookies, you may end up with a banana nut muffin, you may end up with a little cherry tart. And depending upon whether that tart is cherry or strawberry is going to tell you something about the starting materials and how they came through.

Q. And in the process of looking at those samples, are there ways to identify whether or not a finished product may have come from the same source?

1 Α. Only--2 MR. HOUGH: We'll object as to 3 relevancy. 4 THE COURT: Well, I can't tell where 5 we're going. Overruled, go ahead. 6 Only if it is fairly unusual. There is some Α. 7 work on trying to establish back to a single I haven't trusted much of the data 8 9 that I have seen so far on that. However, 10 there are some reactions which are pretty 11 unusual in a geographical area which can afford you to say that it's a higher possibility that 12 13 that particular sample came from this 14 particular individual. 15 In your duties as for the DEA in the Q. 16 laboratory, that consists of analyzing samples. 17 Correct? 18 That is the primary duty, yes. Α. 19 Q. Are there secondary duties? 20 Α. Yes. 21 What are those? 0. 22 Α. I am involved in the investigation of suspected clandestine laboratories, I also teach agents 23 24 and investigators in safety training, how to 25 properly protect themselves against any kind of

physical harm from the chemicals when they do
the seizure. I'm also heavily involved in the
training of state and local and also our own
chemists in the area of analyzing drug
laboratories, interpreting that information and
reporting it in a concise manner for court.

- Q. And when you say reporting it, are you meaning testifying or preparing your--
- A. Written report and also testifying, yes.
- Q. And as part of your duties with the DEA, do you also put on seminars or continuing-type educational activities?
- A. Yes, I have.

- Q. Of what nature?
- A. I have been invited to Australia to participate in a two-week training course there for their local law enforcement in safety training. I also spent a week talking about chemistry and analytical methodology to chemists from New Zealand and Australia. I was invited to speak at an international symposium in Los Angeles at UCLA on methamphetamine laboratories. I was invited to speak in New Zealand on current clandestine drug lab trends in the United States. I've presented a workshop at the

- American Academy of Forensic Scientists regarding general trends over ten years on methamphetamine labs.
 - Q. And with respect to that American-- what did you call it?
 - A. American Academy of Forensic Scientists.
 - Q. And what is that?

- A. That's a-- essentially a U.S., United

 States-based forensic association that pretty
 much encompasses all of the disciplines of
 forensic science; forensic odontology, which
 would be bite mark analysis or identification
 through teeth. Forensic psychiatry, forensic
 engineering, criminalistics, which would
 involve blood typing, hair and fiber. And also
 controlled substances, drug labs, fingerprint
 examinations, things like that. That's the
 whole ball of wax.
- Q. And are you a member of the American Academy of Forensic Scientists?
- A. No.
- Q. And when you were invited to-- were you invited to speak at that or just attend there?
 - A. Yes, I was invited by Doctor Barry Logan, who at the time was running the Washington State

1 Toxicology Department. He is now the director 2 of the Washington State Patrol Crime 3 Laboratory. 4 0. And do you recall whether or not that American 5 Academy of Forensic Scientists meeting you just 6 referenced would have been in February of 1998? I believe it was in '98. It was in San 7 Α. 8 Francisco. 9 And your participation in that particular event Q. 10 was as a DEA officer or as a member of CLIC? 11 That would have been as a -- a DEA chemist. Α. 12 And what were you asked to provide Q. 13 demonstrations on or do at that academy, American Academy of Forensic Scientists? 14 15 Again, I was asked to provide a ten-year Α. 16 retrospect of clandestine methamphetamine 17 laboratories, the types of methods that had 18 been used in the past, the types of methods 19 that were currently being used, display 20 analytical data supporting those routes and 21 different types of things. 22 And were you allotted a certain amount of time 0. 23 for which you were to give your presentation? 24 Yes. I was given about 45 minutes to an hour. Α.

And do you know how the people that were in--

25

Q.

1 do you know approximately how many people were 2 in attendance at that meeting? 3 Α. At the American Academy meeting? 4 Yes. Q. 5 Thousands, 2 or 3,000 probably. Α. 6 And in what type of facility was it held at? Q. 7 Α. It was held at one of the major hotels in downtown San Francisco. 8 9 And I've never been to San Francisco, but is 0. 10 there a major hotel that can hold 2 or 3,000 11 people there or are they congregated together? 12 Well, that's-- the hotel is where the meetings Α. 13 were being held at. Whether they all stayed at that hotel or not-- I know a couple of my 14 15 friends didn't stay at that hotel, they stayed 16 elsewhere. And when you gave your presentation, was it 17 Q. 1.8 like in a big ballroom or a big large area? 19 Α. No, it was a room about this size. 20 And do you know how people were allowed to Q. 21 participate as an attendee at that Academy 22 meeting? 23 Α. I was just a speaker. The mechanics of who and 24 what and where was done by the Academy and by 25 I just provided a service. Doctor Logan.

- Q. And do you know whether or not the attendees had to be law enforcement or could they be members of the general public?
- A. I have no idea.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. And when you did your presentation, did you use visual aides like photographs or a screen or anything of that nature?
- A. It was a power point presentation.
- Q. And when you talked about the clandestine laboratories, you indicated that it was-- I believe you said three parts. How they had been in the last ten years was one part of it?
- And it was a ten-year retrospect, so it Α. Yes. went back about ten years to see how methamphetamine was commonly manufactured at that time. Talked about various legal decisions affecting sentencing, we talked about regulations that DEA and states had incorporated to regulate the chemicals to make it more difficult for the manufacturer to obtain their supplies. Talked about various different routes of manufacture, different chemical processes. And from within those chemical processes, the different types of chemical markers which they could use to

identify back to that particular route.

- Q. And in doing your presentation, was that done by all research that you had personally done or did you base anything upon readings or writings of other individuals?
- A. A major portion of it was based on personal experience. The references regarding the scientific literature, of course, came from the scientific literature. Some of the reaction mechanisms and things, other people had already reported and identified. If I reported them, then it's probably because I ran the same reactions, saw the same products. And it produced nice data, so I could show it nice and pretty on my slide.
- Q. And in your duties as you currently are as a senior forensic chemist, do you have various research materials available to you at work?
- A. I have a limited amount.
- Q. And what does that consist of generally?
- A. We do have a library, the library has some out-of-date copies of general organic chemistry, along with some of the other chemistry journals. We do actively receive the American Academy's journal, which is called the

1 Journal of Forensic Scientists. And we also receive an internal publication, the DEA does, 2 3 called Microgram. And that's pretty much it. What type of information is generally contained 4 Q. 5 in the Journal of Forensic Scientists? 6 is it published on a-- what type of frequency? 7 Α. I believe it's published every two months or 8 every six weeks or so. 9 And do you know what type of information is 0. 10 generally in that publication? 11 It runs the full gamut of forensics. There Α. 12 would be articles about DNA analysis and 13 looking at genetic populations. There would be 14 articles on odontology, there would be articles 15 on pathology, psychiatry, engineering, 16 controlled substances, toxicology. I mean, it 17 just runs the gamut. It's one of the, as I 18 said, the U.S.-recognized forensic group. 19 And do you know, have you ever contributed any Ο. 20 writings or -- or projects to that journal? 21 Yes, I have. Α. 22 And how do you go about doing such Q. 23 contributions? Write the paper, it then goes through an 24 Α. 25 internal review with our agency. Once it

completes that review, any changes or suggested changes are made, the paper is then sent to the current editor of that journal, the editor receives it. He then takes the paper and he has a panel of peer reviewers which he ships the paper off to. They read the paper, they evaluate whether the content is new and original, whether it's reproducible to make sure that you haven't overstated the facts from your data. And then it is either accepted or rejected or rejected with comments or-- or changes to be made.

Once it gets past that phase, if it's outright rejected, then you're pretty much out of luck with that journal. If it's rejected or accepted, I guess, based on the premise that you will make some changes to it, maybe in writing or in structure, once those changes have been made then the paper is accepted. Very few that I ever know of are ever accepted first time around.

Q. And do you know if there are limitations on who can contribute or submit papers for editorial consideration?

MR. HOUGH: Judge, we'll object to

1 relevance. 2 MR. RORK: Judge, it has to do with 3 items Mr. Pickard-- that I-- that the 4 Government seized from Planet Self-Storage and 5 other locations that they've offered for this jury to consider. 6 7 THE COURT: Well, proceed, but why 8 don't you move to it. 9 MR. RORK: I'm attempting to, Judge, 10 to lay a foundation. 11 Okay. May I have the question again, please? Α. 12 (BY MR. RORK) Yes. Are there any limitations Q. 13 on who can -- or restrictions on who can submit 14 papers to what we were talking about now I 15 believe was the American Academy -- or Journal 16 of Forensic Science? 17 I'm-- I don't know. Α. 18 Do you know if it's limited just to law Q. 19 enforcement? 20 Α. I don't know. 21 How many papers have you submitted to that Q. 22 during your work? 23 I have had two papers published in The Journal Α. 24 of Forensic Scientists. With respect to the association CLIC, does it 25 Q.

put out a monthly newsletter?

A. We put out a quarterly journal.

- Q. And what does it basically consist of?
- A. It consists of new regulatory information and tries to incorporate information regarding the field of clandestine drug laboratories that a lot of the smaller agencies, state agencies and local agencies, may not have the resources to find, such as federal registry notices of pending action on a drug that they may want to control or a precursor that they may want to regulate.

There will be sometimes news clippings of incidences which happen safety-wise in an area which may warrant the attention of the members to kind of keep a heads-up to be safe. We also publish original papers and original commentary from submitters.

MR. RORK: Your Honor, I know we've been in here since 9:30. Do you want me to continue or do you want me to take a morning break?

THE COURT: Well, we might take ten minutes at this time and then-- and then come back. Let's recess for ten minutes, ladies and

1 gentlemen. Mr. Bailiff. (THEREUPON, a recess was had). 2 3 THE COURT: All right. You may 4 proceed. 5 MR. RORK: Thank you, Your Honor. 6 0. (BY MR. RORK) You were testifying regarding 7 the contents of the journal that was put out by 8 CLIC and you had gotten down to-- it was after 9 news clippings and some type of editorial 10 articles and you had a few other items. Do you 11 recall what those were? 12 Α. Original research where an individual might 13 examine a particular aspect of a reaction, 14 analytical processes where they could identify 15 by-products or other types of materials. whole basis for the Journal's existence was as 16 17 a vehicle for a rapid dissemination of this type of information to the field. 18 19 Unfortunately, when you publish in a 20 journal like the Journal For Forensic Scientists or The Forensic Science 21 22 International, there's often somewhere between 23 one to one-and-a-half years of lag time from 24 the time you submit that information until it

actually reaches print. With our journal, if

we get it in right, we get it reviewed, we can have it out in about 90 days or the next journal.

- Q. So the primary function of the CLIC is to expedite the dissemination of information in all of those topics to the members?
- A. That's correct.

- Q. And with respect to the membership that you previously described of the-- of the CLIC, is it similar where there's an application process and then they're screened to see if they apply?
- A. There's an application process, there is a letter of verification required from the individual's employer or supervisor which states that, yes, this individual who is applying for a membership is actively involved in the investigation and analysis of clandestine drug lab material.

Further, once we receive those applications, we are pretty much a small group of like-minded individuals, we all know pretty much each other. We then embark upon a verification process behind the scenes where we will contact other members in that area and seek input from these individuals as to whether

1 they truly have a need to have that 2 information, are they actually working drug laboratories, things like that. 3 And you had talked a little bit about that 4 Q. 5 there was some -- precursor regulations was part 6 of the publications in this CLIC journal. 7 would that involve? 8 Α. That would involve the reprinting of federal 9 registry notices as to the intent of the DEA to 10 restrict or list or control a particular 11 material. 12 Q. And would it be limited just to methamphetamine 13 or would it involve all precursors? 14 Α. It-- no, it's not limited to methamphetamine, 15 but it borders on the emphasis of 16 methamphetamine. It also would include such 17 materials as might be popular at this 18 particular time that we're seeing a lot of. 19 For example, there's a tryptamine and another compound that we have been seeing a lot of 20 21 which is not -- are not controlled substances. 22 Recently DEA published an intent that they were 23 going to make them emergency schedules. 24 That is information that our chemists 25 need to know for charging purposes or if they

2.0

get inquiries by their local enforcement officers as to the control status, or their local prosecutors as far as controlled status is concerned.

- Q. And with respect to the tryptamine that you were just discussing about, there's been a lot of testimony in this trial about various tryptamines. And are you familiar as your duties as a chemist with the various tryptamines and their compounds?
- A. I'm familiar with some of them.
- Q. And when you indicated that the-- for instance, the example you gave was a current tryptamine that was not a controlled substance, can you tell me what that involved, that tryptamine involved, the bulletin or publication that they were seeking emergency regulations for.
- A. The compound on the street is known as Foxy

 Methoxy, it 5-methoxy-diisopropyl tryptamine.

 It is commonly being used in the rave dance

 scene. It is not a controlled substance. I'm

 not sure that it is clandestinely being

 manufactured that I know of, it's being

 received directly from chemical suppliers. It

 has become a problem, and the agency is seeking

to make that an emergency controlled substance.

- Q. I'm going to hand you what's been previously marked as Exhibit P-20 that's been identified in the record as a list of compounds that were manufactured, used, ingested or distributed by Gordon Todd Skinner. And can you view that quickly with respect to that tryptamine, 5-methoxy whatever you just said, and see if that's listed on there. I think under Paragraph No. 2, there's some mention of some things with the number 5 in it. Do any of those in Paragraph No. 2 relate to what you just talked about?
- A. On Page 1, No. 2?
- O. Yes.

- A. Is that what you're referring to?
- Q. Yes. Are those things that have a 5 in front of them, are those referencing that drug?
 - A. Well, No. 5 evidently refers to the compound 5-methoxy-alpha-methyl tryptamine. And all these other compounds probably are the synonyms or other chemical names by which that compound is known as. Under No. 5, the alpha, n-dimethyltryptamine, neither of those compounds are the one that DEA is seeking to

- 1 regulate in that federal registry notice.
- Q. So 5 would not be one?

about?

3 A. No.

4

5

6

7

9

10

11

12

13

14

15

24

- Q. Under No. 8, there's a number of items marked meth something. Are any of those ones under No. 8 on Page 1 referencing what you're talking
- 8 A. No.
 - Q. I guess I will have you look at Page 2 and it appears to be-- are any of those referenced in No. 9 or No. 11 what we were-- you were just talking about?
 - A. No.
 - Q. No. 12 on Page 2, was any of those "methies" the ones you just referenced?
- 16 A. No. 12?
- 17 Q. Yes, on Page 2.
- 18 A. No.
- 19 Q. Have you finished looking at Page 2, have you?
- 20 | A. Yes.
- Q. Would you look at Page 3 and see if there's anything on that page that refers to it?
- 23 A. Yes, it does, No. 13.
 - Q. No. 13. And what is No. 13 corresponds to the-- what you talked to-- talked about?

1 No. 13. Α. 2 All of the items listed in there? 3 Α. Well, the-- the first name is probably out of 4 the Merck Index or something like that. 5 subsequent names are synonyms, other names that 6 that compound can be called, may have been 7 called in the literature, things like that. 8 Q. For purposes of the record, would you please 9 read those? 10 Α. All of them? 11 Q. Yes. 1.2 MR. HOUGH: Well, Judge, we'll 13 object. The document speaks for itself. This 14 is cumulative and irrelevant. 15 MR. RORK: Judge, with respect -- with 16 the record-- when the prosecution put on items 17 for the record, they needed to read it into the 18 record for the purposes of the record, and 19 that's the same purpose I'm doing it here. 20 There's like four items in that paragraph. 21 MR. HOUGH: The document speaks for 22 itself, Judge. 23 THE COURT: Well, go ahead and read 24 them. Quicker to do it that way probably. 25 THE WITNESS: I will be reading it

1 with the punctuation and spelling if need be. 2 THE COURT: All right. 3 I'm sorry, I didn't name these. The first one Α. 4 is Indole, 5 3-{2-(Diisopropylamino)ethyl}-5-methoxy; the 6 next one would be capital N, capital 7 N-diisopropyl-5-methoxy tryptamine; the next 8 one is 3-{2-(diisopropylamino)ethyl}-5-methoxy 9 Indole; and finally 5-methoxy- capital N, 10 capital N-diisopropyl tryptamine. 11 Q. (BY MR. RORK) And essentially what's contained 12 there-- what you've read are four different--13 what do you call those, scientific words or --Essentially those are four different ways to 14 Α. 15 name that particular compound. 16 Ο. When it-- and when it's four different ways to name it, does it consist of four different 17 18 types of ingredients in the compounds or just--19 Α. No. 20 So what-- could you give me an analogy? Q. 21 mean, is it a different make or a structure? 22 Well, what -- what has happened is that early on Α. in the chemical field, there was no naming 23 24 convention, no manner of which any kind of 25 standardized process was involved to name

compounds. Therefore, a researcher would name it as they were taught or as they felt best described the molecule. And you have researchers working in Europe, you have them working in the United States, you may have them working in Russia, and they're all naming things a little bit differently. When I went to college, we learned about what was known as the IUPAC, which is a naming convention by which common— or compounds are now named. The different fractions of the molecule are given certain weights as to where they would appear in the name to try to uniformly establish a means by which these chemicals are identified.

And-- and, for example, if you were to go out and do a literature search on 5-methoxy-N,N-diisopropyl tryptamine, unless that name was used in literature dating back into say the '50s, you wouldn't find that literature. You would have to search for all of these terms, because these are the possible terms that it may show up in the chem abstracts database or Bileschtein (phonetic) or anything like that.

Q. So while they may contain different compounds

- within themselves, they're just a different person's manner of describing the same thing?
 - A. No, there's no different compounds in there.

 It is one single cup. This is a Styrofoam cup.

 We can call it a cup, we can call it a drinking glass, we can call it a Styrofoam cup. And it's still what it is, it's one thing, it's a cup.
 - Q. And that would be the analogy to what was then in 13?
 - A. That's right.

- Q. And with respect to-- limited, again, just to this same tryptamine that's in No. 13, can you glance through the rest of the paragraphs on that page and see if there are or not any other ones similar.
- A. Well, they're all similar, but none of them the same ones.
- Q. Okay. And other than the same one, will you go to the next page and just succeeding pages and look and see with your expertise if there are any other same compounds listed in the numbered paragraphs that you've just described.
- A. I've read through No. 163, I don't see any other occurrence of that compound.

	1	
1	Q.	And with respect to ones that are similar, what
2		do you mean by similar in nature of compounds?
3	Α.	The tryptamine derivatives, they have the basic
4		moiety of a tryptamine molecule present in the
5		structure.
6	Q.	And is there currently existing any type of
7		scientific number of how many tryptalines
8		(phonetic) compounds are known to mankind?
9	Α.	I don't I'm not aware of any.
10	Q.	I mean, when you say similar ones to that
11		5-methoxy that you talked about.
12		MR. HOUGH: Objection, relevance.
13		THE COURT: I'm going to sustain it
14		now. We're getting too deep in this to
15		MR. RORK: Well, Judge, it goes with
16		respect to all I'm asking him is the similar
17		ones. I'm not asking him to go through and
18		identify them, but just what are the similar
19		ones as it relates to the effects and in that
20		nature is the purpose of question.
21		MR. HOUGH: Still irrelevant, Judge.
22		THE COURT: I sustained the
23		objection.
24	Q.	(BY MR. RORK) With respect to, then, the
25		precursor regulation that you were discussing

brought out, earlier, this was an example of this item you called-- I believe you referred to it as a nickname for this chemical compound.

What did you call it?

- A. First of all, this is not a precursor, this is an actual substance which is being abused. In the journal we will publish federal registry notices which deal with the regulation of precursor or essential chemicals and reagents. And we will also notify of pending regulations to make a substance controlled.
- Q. And with respect to this particular compound, what did you refer to it, as a nickname of it?
- A. Foxy, F-O-X-Y, dash methoxy.
- Q. And are you familiar with or aware of any other street names it's been referred to by the raves, that you've indicated that you don't really use that.
- A. I've also heard it called just simply Foxy.
- Q. Have you ever heard it referred to as called Frank?
- A. No.

Q. And when you indicate that the precursor information would be sent out, does that mean

the notices in this CLIC magazine would deal with what items are used to make this or what do you— what do you mean when you refer to—that the precursor information will be distributed?

A. Two different things. The precursor information doesn't have anything to do with this particular compound. These are published federal registry entries of the intent of the Drug Enforcement Administration to somehow either regulate or control a material. The federal register entries that the DEA is making that I'm interested - and from what I understand they do quite a few - deal with the regulation and control of either precursor chemicals or essential reagents for reactions to make methamphetamine or any other kind of controlled substance.

And secondly, the intent of the Drug
Enforcement Administration to place under a
scheduled status a substance which is currently
being abused by the public.

Q. And with respect to this one that you've referred to as the 5-methoxy, does it contain a substance also known as alpha ET?

- A. 5-methoxy-- no, it's called Foxy Methoxy to make it simple, and alpha-ethyltryptamine, or AET, are two totally different compounds.

 Alpha-ethyltryptamine is a controlled substance.
- Q. And--

- A. Now, that doesn't prevent it from being present as a mixture in a final form of which somebody might consume for recreation. However, the federal register notice specifically addresses that this compound is going to be placed under emergency schedule by the Drug Enforcement Administration.
- Q. Have you ever authored yourself or submitted articles for consideration to be published in the CLIC magazine?
- A. Yes, I have.
- Q. And what is the process used to do that?
- 19 A. That I do to do that?
- 20 Q. Yes.
 - A. I find something that's interesting that's
 worthwhile to publish, I will write it up. I
 will submit it to my supervisor, who then goes
 to the laboratory directly for a cursory
 evaluation as to whether it's meritous (sic) or

not. It may then be reviewed locally within our laboratory for form, content, conciseness of thought, application.

Once it has cleared my local laboratory, it is sent back to our main headquarters at Washington, D.C., to program manager. The program manager receives it. He will then—he or she will then disseminate it to reviewers and other field laboratories around—DEA field laboratories in the United States. They will again review the content for conciseness, methodology, make sure that it's worthwhile to publish.

They will then issue their comments back to headquarters. If there are changes that need to be made, that comes back to me for changes. If not, then it is accepted and it's authorized for publication. Generally speaking, if a paper is submitted to the CLIC journal from outside the DEA system, it does undergo a peer review by our members that I would— in my case when I was editor the— or peer review would be by members who are knowledgeable in that particular field, and they would do the peer review.

In the case of DEA chemists, because I am aware of the substantial level of scrutiny that that paper gets before it ever gets to the journal, then I will likely during my tenure go ahead and publish it without having any other kind of a peer review.

- Q. And what year or time period do you recall that you were the editor of the CLIC journal?
- A. I was editor from 1990-- well, since inception of the group when we divvied up the jobs, I started out as the editor, which was about 1989 through 2001.
- Q. And with respect to the types of articles that were presented, for instance, in your regard, the one that you presented in February of '98 at the program you talked about with the meth labs and the ten-year usage, was that something that you also presented to either the CLIC magazine or other journals to be published?
- A. No.

- Q. What topics have you presented to the CLIC journal to be published?
- A. Extraction procedures; to take a single powder sample, to extract it, to examine different types of compounds that might be present, to

NORA LYON & ASSOCIATES, INC. 1515 S.W. Topeka Blvd., Topeka, KS 66612 Phone: (785) 232-2545 FAX: (785) 232-2720

1 capitalize on solubilities, whether they're 2 acids, bases, polar or nonpolar. And to do 3 identification by infrared spectro--4 spectrophotography -- infrared spectroscopy, 5 we'll go there. 6 Q. Have you presented any paperwork, do you 7 recall, on the tracking of precursors? 8 Α. No. 9 0. As editor of this magazine, CLIC, do your 10 duties coincide with your work at DEA or do 11 they overlap? 12 Α. Isn't that the same? 13 0. I don't know. I mean, coincide and overlap, isn't that the 14 15 same? 16 Well, it can be depending upon the definition. Q. 17 What do you describe your duties? 18 Well, if they coincide, to me that means that Α. 19 they would overlap. 20 Okay. And can you describe for us how that Q. 21 works in your situation? 22 I'm not quite-- I'm not quite sure what you're Α. 23 asking. Sorry, Mr. Rork. 24 Well, you have your obligations as a DEA Q. 25 officer?

- A. Yes.
- 2 Q. That's your duties?
- 3 | A. Yes.

- Q. And as your duties as the CLIC member, is that a separate organization from your DEA employment?
- 7 A. Yes, it is, absolutely.
 - Q. And as being separate employment, do you have to do the work there separately from your DEA work?
 - A. Well, first of all, the-- my activities within CLIC is not an employment, there's no compensation, it is specifically volunteered.

 There is a commingling at time of the activities. Sometimes an individual will call me and request information regarding a particular synthesis which might be unusual or something which might be rather obtuse and-- and hadn't seen for quite a while, in which case I would mention to them that it might be nice if they could submit that to the journal as a submission.
 - Q. So they can coincide then?
 - A. Yes, they-- they have a tendency to mingle once in a while.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. And with respect to the synthesis that you indicated that was unusual, in general, what is a synthesis as it relates to your activity and -- and controlled substances? What does synthesis consist of? Α. What does synthesis consist of? Yes. Q. Synthesis consists of taking one or more Α. chemicals and reacting them in some manner to create a second compound. And with respect to the meth labs that you have Q. experience in, do the operation of the meth labs involve synthesis of anything? Α. Absolutely. And the synthesis involved, is there more than Ο. one type of synthesis? Α. Absolutely. 0. And when you discussed that if someone had contacted you about an unusual synthesis, what do you mean by that, for example?
 - A. Perhaps an unusual source of red phosphorous or hydriodic acid, of iodine, which are essential chemicals for that particular reaction.

 Unusual sources of the precursor pseudoephedrine or ephedrine. If an individual

happens to run into a laboratory, for example, as I did last March, a year ago March, where an individual was using a process using phenyl-2-propanone, which is a process that we hadn't seen in probably 10 to 12 years. That is something of note.

We've had instances of these types of methamphetamine labs using the phenyl-2-propanone talked about coming out of our Dallas, Texas, laboratory.

- Q. And in your duties either as the work for the DEA or for CLIC, do people contact you from the general public and ask you for information?
- A. Not much from the general public, very rare, very seldom.
- Q. What are the normal types of contacts that you may receive regarding information concerning either, let's say, for instance, the CLIC activities?
- A. Forensic scientists in the field working for legitimate police or law enforcement laboratories who, generally when they call me, they run into a problem with their analysis, they don't understand something about the evidence that they've received or they're

1 wanting a-- a standard spectra or want me to 2 look at something regarding their analysis to 3 make an interpretation to help them out. 4 Q. Do you work with any schools in their research 5 departments? 6 Α. No. 7 And in the library that you used or you have at Q. 8 work, you've indicated that you have an article 9 called the Microgram? 10 Our library has a large collection of chemical Α. 11 literature. Unfortunately, it's old. Our chem 12 abstracts file stops about 1958. At that time 13 I think it was being published maybe once a month or so. Now it's being published, you 14 15 know, weekly with different fields; weekly for 16 organic chemistry, weekly for biochemistry, 17 because things are changing so rapidly. unfortunately, we just can't keep up with it. 18 19 And do you accumulate, yourself, articles from Q. 20 different sources dealing with clandestine 21 labs, for instance? 22 Yes, to some degree. Α. 23 And with respect to the articles that you keep, Q. 24 are they used in your work?

They are used-- yes, they're used in my work.

25

Α.

1	Q.	And do you have them categorized in a certain
2		manner or are they just by publication or by
3		subject matter?
4		MR. HOUGH: Judge, we'll object.
5		This is irrelevant.
6		MR. RORK: Judge, I'm asking about
7		the articles that he uses in his work in
8		clandestine labs.
9		MR. HOUGH: And how he categorizes
10		them in his personal library would be
11		irrelevant to the issues before this Court and
12		jury.
13		MR. RORK: It has to do with, Judge,
14		with respect to the items that the Government
15		wants the jury to consider relevant that they
16		seized and marked as evidence and how they were
17		obtained.
18		THE COURT: Well, let's plow ahead
19		here. We've devoted a lot of time to this.
20		THE WITNESS: I'm sorry. May I
21		answer it then, Your Honor?
22		THE COURT: Yes, sir, you may.
23	Α.	Yes, I have a collection about 600 or so
24		journal references that I have computerized by
25		key word and topic. Unfortunately, it's

1 probably about ten years out of date.

- Q. (BY MR. RORK) And before they were categorized by key word and topic, you had to take like a written publication and view it to then put it into the computer. Is that how you did it?
- A. Well, that is-- I still do it. That's how I did it. It's only in my database if I physically have a copy of it.
- Q. And I'm sorry, I don't understand what you just said.
- A. I only had a-- I had a copy of the paper. The only way that it gets into my database is if I physically have a copy. If I'm just reading it out of a journal or looking at it, it doesn't get entered into my system, because that allows me by having a copy to go and read that copy know right where that section is.
- Q. And do you also keep in-- your collection of hard copies that you use before you enter them into your database for -- for prior reference?
- A. Uh-huh, yes, yeah.
- Q. And other than categories and topics with respect to clandestine labs, would that include like the location of the lab and the source of the items used or what would it generally

consist of?

- A. No, generally the papers— at that time there weren't a whole lot of papers on clandestine laboratories. The papers were broke down according to the controlled substance the paper was talking about. So if it was heroin or opiates or morphine, it would be in one file.

 Amphetamines would be in another file.

 Marijuana would be in still other file. I had things about computers and databases and operating systems and things like that also there.
- Q. So essentially the basic way that you would categorize the items, as you've indicated, would be by the subject matter?
- A. Oh, that would-- that worked for me. Different people use different methods. That, prior to the computer, seemed to work best for me.
- Q. With respect to the inquiries that you have from other people in the CLIC magazine, did it have like a contact if someone wants to receive information from a member of CLIC, how to do that? I mean, is it depicted in the journal itself?
- A. Why would they want to contact a member? Do

you mean to publish?

- Q. With respect to the publication, does it have on the inside the normal language about here's the home office, here's a way to reach us, or anything like that?
- A. There is a side light or side panel which lists the current officers. There's a disclaimer and a copyright notice at the bottom of the journal indicating how we prefer to have submissions made to the journal.
- Q. And while there may be a disclaimer made for submission to the journal, is there any information on how either an author of an article can be contacted or a member can be contacted?
- A. There's information if we publish— if a paper is published, a research paper or a technical note or analytical methodology—type paper, the author, their affiliation, agency, city is generally included. I used to put phone numbers or maybe e-mail addresses down, also.

 But those became rather fleeting with area code changes and Internet service provider changes, so it's just basically Roger Ely, DEA Western Laboratory and probably the street address. As

1 far as contacting individual members, the 2 membership roster is published separately from 3 the journal once a year and only goes to 4 members. 5 THE COURT: Mr. Rork, why don't we 6 break for lunch. Ladies and gentlemen, let's 7 break until about 1:20 and then we'll-- we'll 8 start again. We'll try to get started at 1:20. 9 Mr. Bailiff. 10 (THEREUPON, a luncheon recess was had). 11 THE COURT: Mr. Rork, do you have something you wanted to talk to the Court 12 13 about? Would the attorneys--14 MR. RORK: We can do it at the next 15 break if you want to and go ahead and start 16 with this. 17 THE COURT: All right. That will be 18 fine. 19 0. (BY MR. RORK) With respect to the issues 20 involving submission of articles, do you, in 21 the course of your duties as a DEA agent, 22 receive inquiries from various parties outside 23 the DEA for information? 24 First of all, I'm not a DEA agent, I'm a DEA Α. 25 chemist. And yes, I do receive inquiries from

1 outside of our agency regarding matters 2 applying to chemical analysis, chemical trends, 3 clandestine laboratory safety regulations and 4 laws. 5 Q. And when you indicated you're not a DEA agent, 6 you're a chemist, is that -- is there a 7 difference? 8 Α. Yes. 9 And at the time you worked in the San Francisco Q. 10 laboratory in the period that you've indicated, 11 did you work with Karl Nichols? 12 Α. Yes, I did. And as a chemist, the-- is there a list that's 13 Q. 14 put out for people to contact you for either 15 DEA or for CLIC or how does that occur, do you 16 know? 17 Specifically, if an individual wants to get Α. 18 ahold of me through the laboratory, they can call the laboratory. The people within CLIC 19 20 who want to contact me know to contact me

Q. And do you recall in 1995 whether or not at that time you had a computer and an e-mail address?

through the laboratory or through an e-mail.

A. Yes, I did.

21

22

23

24

- Q. And in 1995, do you recall if your telephone number was (415) 744-7051?
- A. It was, and it remains the same.
- Q. And that-- would that be extension 29?
- A. That was my extension at the time, yes.
 - Q. And do you know if in 1995, about that time period, if your work hours were 7 a.m. to 3:30 p.m.?
 - A. And they still are, yes.
 - Q. Now, I would direct your attention back to the first part of 1995. Do you recall receiving any contact by telephone or otherwise from somebody that identified themselves to you as William Leonard Pickard?
 - A. Yes.

- Q. And how did that come about, do you know?
- A. Initially, I was contacted by Doctor Alexander Shulgin, who indicated that there was a researcher at the JFK School of Government at Harvard who was looking at doing some research into the use of the Internet for the purposes of procuring recipes or instructions to manufacture illegal substances, for obtaining chemicals and precursors, and also for trafficking those substances via the Internet.

One of my areas of interest happens to be in that area and monitoring things that occur, such as web sites and discussion groups that's on the Internet. I've been used many times as a resource for that particular material and I've done training in that material.

Doctor Shulgin asked me if it would be okay if he shared my telephone number with this individual. I don't recall offhand if he named Mr. Pickard at that time by name or that it was just an individual, but I indicated that, yes, it was, for the purposes as I understood them to be. I want to say within the next day or so, certainly within the week, I was-- I received a phone call from Mr. Pickard.

- Q. And do you recall at the time of that phone call what the nature of the inquiry dealt with?
- A. The impression I had of the phone call was it was more or less a introductory phone call; this is who I am, this is what I'm interested in, this is what I'm doing. I have been referred to you that you might be able to provide this information for my research project. And, you know, what can you help me with, would it be okay if I use you as a

1 resource.

- Q. And as was related to you by Doctor Shulgin, did Mr. Pickard indicate that he was, in fact, a student at the Kennedy School of Government and was doing some research into those areas you've indicated?
- A. I believe I said that already, yes, he was.
- Q. And that's what Doctor Shulgin had told you he was doing?
- A. Yes.
- Q. And when you talked to Mr. Pickard, did he reaffirm that that was the areas he was looking into?
- A. He indicated the-- that he was at the JFK

 School of Government at Harvard. However, the

 emphasis of his phone call and the information

 he was interested in during the course of that

 phone call shifted from what was originally

 represented to me by Doctor Shulgin.
- Q. And do you recall what it shifted to?
- A. It shifted to illicit fentanyl laboratories and fentanyl analog laboratories.
- Q. And do you recall how the nature of the conversation shifted during his talks with you that first time to the fentanyl?

NORA LYON & ASSOCIATES, INC. 1515 S.W. Topeka Blvd., Topeka, KS 66612 Phone: (785) 232-2545 FAX: (785) 232-2720

A. Yeah, I'm-- I'm trying to recall. I believe that we were talking in general terms about controlled substances. And I believe Mr. Pickard may have said something in passing about fentanyl and, I believe, made the comment that we hadn't had a recent fentanyl laboratory in the United States back into a certain time, along that line. We hadn't had one for a while. And when, in fact, we had had a major laboratory down around Wichita, Kansas, probably within three or four years. So that would have been about 1990, 1991, somewhere around that time. And I had advised him of that particular lab.

I also advised him that fentanyl was a-a growing problem in the former Soviet Union,
that they are seeing a lot of illicit
laboratories there being run out of college
chemistry departments by college students,
including some who had won a chemistry
competition were actually manufacturing
fentanyl. And he was interested.

- Q. And did Mr. Pickard indicate to you what he was-- or asked you to send him anything?
- A. Did he ask me to send him anything? No.

- Q. And during the conversation, did you discuss or indicate to him any materials or items that you may have in relation to this fentanyl issue?
- A. Regarding the-- the laboratory that was in Wichita, Kansas, the defendant who was in that case was named George Marquardt. Mr. Marquardt was the subject of an ABC News, Dateline segment, oh, a couple of years earlier where the reporter sat down and spoke with him from prison about what he had done, how he had done it and his attitudes in general about drug trafficking and things like that.

I received-- I saw the tape at a training session, I had contacted an agent who presented it, he gave me a copy of it, which I've incorporated into my training. I had asked Mr. Marquardt-- or Mr. Pickard, I'm sorry, Mr. Pickard if he had ever seen that segment, he indicated that he had not. I advised him he could probably get a copy from ABC

News/Dateline or I could burn him a copy from the one that I had. I don't know if it made much of a difference, but I volunteered-- at a time, I volunteered to send him a copy of that tape.

- Q. And I will have you look at what's been admitted into evidence by the Government and marked as Exhibit No. 549 and ask you if you could examine that package and the contents inside to see if it looks familiar?
- A. The box is a box that is addressed to me at the DEA Western Lab in San Francisco, excuse me, from Hewlett Packard's Corvallis Division up in Corvallis, Oregon. This was a return box used for a laptop computer that I had sent out for repair. I reuse boxes around the lab, so that's what the tape got thrown in.

Inside there is a Fuji tape with a typed label on the spine saying ABC, Day One, the Evil Genius. There's also a 60 Minutes segment about Hell's Angels that was also included. There is a handwritten note on a Post-It pad dated 3-13, which also accompanies it.

- Q. And is that handwritten note something that came from you?
- A. Yes, this is what I wrote.
- Q. And for purposes of the record, can you read what the note cyst?
 - A. Certainly. Again, it's dated 3/13. It says, "Leonard, pop some popcorn, sit back for an

entertaining time compliments of Marquardt."

And it's signed Roger.

- Q. After that exhibit had been forwarded by you to Mr. Pickard, do you recall whether or not he, Mr. Pickard, contacted you by phone or e-mail thereafter to discuss certain activities?
- A. He-- he either contacted me by e-mail or by phone, I don't recall.
- Q. Do you recall whether or not after receipt of the video Mr. Marquardt made-- or Mr. Pickard making any inquiries of you concerning procedures Mr. Pickard needed to undertake in order to interview Mr. Marquardt at any Bureau of Prisons location?
- A. No, he made no inquiries to me regarding that.

 I remember he contacted me and indicated that he had received the tape and he had watched it.

 And I remember him saying that he had located Mr. Marquardt at the Sheridan federal prison in Sheridan, Oregon. And I believe at that time he said he was in the process of trying to make contact with Mr. Marquardt to see if he would be willing to talk about his adventures as a fentanyl chemist regarding his— or relevant to his case.

- Q. And do you recall whether or not Mr. Pickard indicated to you that after he had received some letters— or do you recall Mr. Pickard advising you that he did, in fact, establish contact with Mr. Pickard— Marquardt?
- A. Yes. And I don't recall, it was a period of time afterwards, it may have been a month, two months or so. I-- I don't recall the exact dates, but he did make contact saying that he was able to get Mr. Marquardt to open up to him by providing a couple of science books to him. I think one was on mass spectroscopy and interpretation, I don't recall what the other one or two were. But then Mr. Marquardt had typed a single-spaced document, maybe seven, eight pages in length, which detailed his operation and how he performed the synthesis and what he was doing and what he was thinking at the time.
- Q. And do you recall whether or not at any time
 Mr. Pickard may have advised you that he, Mr.
 Pickard, had scanned or viewed around 275
 newspaper articles involving the Marquardt
 occurrence and to see if you wanted to-- any of
 the information from those edits or reviews

that he had done?

- A. I believe he indicated that he had looked through the Nexis/Lexis system, whatever that particularly is. And he may have offered, but I really wasn't interested.
- Q. Do you recall whether or not Mr. Pickard sent to you a copy of the synthesis that Mr.

 Marquardt had sent to Mr. Pickard and your indicating that you would review it at some point?
- A. Mr. Pickard sent me what he represented to be Mr. Marquardt's correspondence with him, he sent me a photocopy of it. And as far as I remember, it was for my information, it wasn't for any kind of review, it was just for my curiosity.
- Q. And did that piece of paper that Mr. Pickard represented to you was from Mr. Marquardt, in fact, not contain information regarding Mr. Marquardt's synthesis used in his fentanyl manufacturing?
- A. You know, I don't really recall. Mr. Marquardt was a fairly fluent, flowery-type of writer, he would like to go on and on about things and wasn't very specific. In honesty, I glanced at

the document, put it back in the FedEx folder and it sat on my counter for maybe two or three years before I finally threw it away.

Q. Let me hand you what's been marked for evidentiary purposes as P-50. And I'm going to open it up and ask you if you would look through the items in P-50 and see if you find anything that may represent the document you referred to that Mr. Pickard had forwarded you purporting to be the synthesis of Mr.

Marquardt?

MR. HOUGH: Well, Judge, we'll object. That assumes facts not in evidence. The witness did not testify he received any synthesis from Marquardt. What he testified to was that Mr. Pickard sent to him what he represented as the correspondence he received from Mr. Marquardt.

MR. RORK: Judge, the question, if the court reporter read it back, I believe would say, would you look through the exhibit and see if contained therein would be a copy of the documents Mr. Pickard sent to you which you indicated were represented as being the synthesis of Mr. Marquardt. This witness

1 earlier testified that the items sent by Mr. 2 Pickard was purported to be from Mr. Marquardt, 3 had to deal with the synthesis process used, in 4 response to my question. 5 Well, this gentleman is THE COURT: 6 here. There's an argument apparently on what 7 he said, let's-- could you tell us what you 8 said and what the situation was so we'll clear 9 that up? 10 (BY MR. RORK) What items did you say Mr. 0. 11 Pickard sent to you and represented it to be 12 of? 13 Α. Mr. Pickard sent me a copy of what he represented to be Mr. Marquardt's response to 14 15 his questions and it was just a photocopy. 16 And did you indicate that in the copy of the 0. 17 correspondence Mr. Pickard sent to you, that 18 Mr. Pickard represented in those contents were 19 items representing the synthesis of Mr. 20 Marquardt? 21 Α. Not that I recall, no. 22 Q. What do you recall mentioned about the 23 synthesis of Mr. Marquardt? 24 What I remember -- what I recall about it was Α. 25 that was one of the facets that Mr. Pickard was

going to ask Mr. Marquardt about. Certainly
Mr. Marquardt didn't want to venture into that
territory, he didn't have to.

- Q. And do you recall whether or not Mr. Pickard ever sent to you documents that purported to be the synthesis process used by Mr. Marquardt?
- A. I don't recall. I just recall the copy of the questions that he forwarded for Mr. Marquardt to answer, I remember Mr. Marquardt's response rather specifically because of the unusual way in which he wrote the response.
- Q. Will you look through those documents in that item number and see if there are any documents contained therein that correspond to either the questions Mr. Pickard sent you a copy of or the answers Mr. Marquardt provided that you recalled.
- A. I seem to remember these two sheets here, questions. And I-- I'm assuming that these were the ones that Mr. Pickard gave Mr.

 Marquardt. There is a-- a response that just simply says Doctor Pickard and it's signed by Mr. Marquardt, two pages long, which is consistent with the document that I saw, or at least consistent with what was represented to

me as Mr. Marquardt's writing. Mr. Marquardt had a tendency not to place a space after his periods when he would end a sentence, which I joked about, to myself at least, as being-conserving space so that he might be able to put more onto a page.

There is another document that says, "I will assume you have your list of questions at hand." That particular typing is different, it does not have— it has a space or two after each of the periods, so I'm not sure if that one is from Mr. Marquardt or not. And then there's another page, it says question— or, "Doctor Pickard, Question 8." Again, we're back to the style of where there is no space after the period, which looks to me to what I remember to be from Mr. Marquardt.

- Q. And those items that I've handed you that you're looking at now, were you shown those prior to today by the Government--
- A. No.

- Q. -- or copies of those?
- A. No. Nope. Haven't seen them since I had whatever documents was sent to me back in '95 I quess.

- Q. And are you making a pile, then, of the documents that you recall seeing?
 - A. Yeah, I can. I mean, there's no individual distinguishing marks on these pages to describe them for the record, but I can make it into two piles if you'd like.
 - Q. That's fine. And then that's when I'm going to make the distinguishing remark.
 - A. Okay. Okay. I would say the bulk of the documents probably came to me, they look familiar to some degree. And again, the typing is-- is consistent with what I remember. Those documents.
 - Q. Okay.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- A. I never saw these three that I'm aware of.
- Q. What I'm going to do for marking purposes,
 P-50a, and I'll place that on one of the three
 documents you've indicated you don't recall.
 P-50b, I'll place that on the other.
- A. I've not seen any of these.
- Q. Right. I'm going to put P-50b on what appears to be a two-page document. Correct?
 - A. Yes.
- Q. And then with respect to the other documents,

 I'm going to place P-50c on what appears to be

a two-page document that starts out with

questions and then they're numbered; is that

correct?

A. Yes.

- Q. And then I will put P-50d on what appears to be a two-page letter to Pickard or you've indicated you've seen, d. And then I will put P-50e on what appears to be-- would you-- does it appear to be that P-50e are these next four pages, Question 8, Question 8 continued, and other-- documents you've seen before?
- A. I'm-- you know, I don't know. There are no page numbers to associate them, so--
- Q. Sure. I'm just putting it on the mark with the ones that you've indicated you may have seen before. And excuse me, sir, if I may. Just so the record is clear, what I've marked as the pile of documents that you've indicated look familiar, the ones you reviewed, that would be P-50c, P-50d, P-50e, P-50f, P-50g, P-50h and P-50i; is that correct?
- A. To the best of my recollection, yes.
- Q. And the three pages -- the two documents that you do not recall seeing before would be marked as P-50a and P-50b?

1	Α.	That's correct.
2	Q.	For your information, were you told or are you
3		aware that the Government Exhibit marked No.
4		549 indicates it was taken from a storage
5		locker called Planet Self-Storage in
6		MR. RORK: Was that Boston,
7		Massachusetts?
8		MR. PICKARD: Uh-huh.
9	Q.	(BY MR. RORK) In Boston, Massachusetts, are
10		you aware of that?
11	Α.	What exhibit is that?
12	Q.	It's the videotape.
13	Α.	Yes, I was aware it was taken out of a
14		mini-storage in Boston.
15	Q.	And do you know whether or not the John Kennedy
16		School of Government is in Boston,
17		Massachusetts, or not?
18	Α.	I it's attached to Harvard, but I'm not sure
19		if it's in Boston proper or not.
20		MR. RORK: Judge, at this time I
21		would move for admission of Exhibits P-50c, d,
22		e, f, g, h, and i.
23		MR. HOUGH: Judge, may I voir dire
24		the witness?
25		THE COURT: Yes, you may.

VOIR DIRE EXAMINATION

BY MR. HOUGH:

- Q. Sir, is it your testimony that you believe at some point you saw documents like these that Mr. Pickard provided you or that these are the exact documents you saw?
- A. Could I take a look at it, please?
- Q. Certainly.
- A. They are similar to documents that I remember receiving from Mr. Pickard with the exception of Defendant's Exhibit P-50g, as in George, which is an interesting description about life on the Kansas plains, making illicit drugs with thunderstorms clapping in the background and the fact that— the whine of steering motors and the clatter of generators in the distance—(Reporter interruption). The whine of steering motors and clatter of the generators in the distance, life doesn't get much better than this.

And I just remember that was a rather romantic notion Mr. Marquardt had taken of his work and was visualizing the-- the prairies and sitting there while he had a reaction running making this very dangerous drug and watching

the skyline. And I remember that specifically.

These others, again, they look consistent with what I sort of recall, I can't tell you whether these are actually them or not.

MR. HOUGH: Thank you. Judge, we would have no objection to the document he can identify, 50g, but we would object to the others for-- on basis of foundation.

MR. RORK: Judge, 50a and b were the ones that he initially identified that he did not recall seeing anything similar. The other ones I've asked for, c through i, were ones he says tended—indicated that they appear to be similar to ones he received, and we would just say that any objection would go to the weight. And Mr. Pickard will also testify those are the documents that he sent to him, I can proffer the Court that.

MR. HOUGH: Well, Judge, at that point certainly there may be a sufficient foundation for admissibility. But based upon the foundation present before the Court, these documents we would submit are not admissible, with the exception of the one he can identify.

MR. RORK: And, Judge, if Mr. Ely is

not here when Mr. Pickard testifies, then I assume the Government— there would be an objection at that point that he's not there, that's why I'm offering them now while he's here present. And the one that the Government pointed to in the blue paper is the one he says he specifically recalls exactly. The other ones, Judge, he says he recalls appear to be similar in form and nature, he can't say they are the exact ones.

MR. HOUGH: Judge, this witness doesn't have to be present in the courtroom when Mr. Pickard testifies to establish, if he can establish, a foundation for the admissibility of the document.

THE COURT: Oh, I believe I will admit all of these documents. You say these are similar to things you received, is that what you've testified to?

THE WITNESS: They appear to have the type of content that I remember. Certainly ones that I had indicated that I-- were consistent were typed in the manner of which I remember, the fact that there was a period and no space following that. Other than that, I--

1 I couldn't tell you. It was a long-winded 2 document and pretty verbose. I do remember, 3 though, the romanticized description of life on 4 the Kansas plains. MR. HOUGH: Judge, we would submit 5 6 that the "life on the Kansas plain" document is 7 clearly admissible. But based upon the 8 follow-up to the Court's questioning, the 9 others clearly are not. 10 MR. RORK: And, Judge, again, he 11 testified earlier there was questions that were 12 asked, he recognized the questions and there 13 were responses and he reviewed a number of 14 materials. 15 THE COURT: Now, tell me again -- I haven't seen these documents, I don't know a 16 thing about them, but c, d and e, whose 17 18 documents are those, were those the--19 Judge, 50-- I guess the MR. RORK: 20

MR. RORK: Judge, 50-- I guess the Government laid them back down here. I will give them to the Court so you can-- 50a and b are three documents he indicated did not appear to be consistent with documents he saw before. 50c through i are the documents that did. And g, I'm putting the blue one on top, is one he

21

22

23

24

1	specifically recalled because of the content.
2	THE COURT: Well, he cannot identify
3	50a and 50b; isn't that right?
4	MR. RORK: That's correct.
5	THE COURT: So we can forgot about
6	those.
7	MR. RORK: I haven't offered those.
8	THE COURT: All right.
9	MR. RORK: That's why I only offered
10	the other ones.
11	MR. HOUGH: Your Honor, we would also
12	submit that under Rule 403 that these would not
13	be admissible documents.
14	MR. RORK: And, Judge, these are
15	documents Mr. Pickard is testifying under and
16	they're documents that were taken from Planet
17	Self-Storage by the agent, seized pursuant to
18	their search warrant, that which item number
19	Government's Exhibit 549 came out of the same
20	locker. And they're documents
21	MR. HOUGH: Judge, every everything
22	seized from that storage locker is not
23	necessarily relevant and admissible in this
24	trial. And, in fact, the Court has ruled
25	certain documents we have offered were

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

inadmissible pursuant to 403, and we would submit that these would fall under that same category.

MR. RORK: And, Judge, there are about 700 or 1,737 other documents down at the DEA somewhere on the second floor that we haven't offered. We have gone through these documents on the time we've had on Fridays, and Mr. Pickard has reviewed the documents and he has picked out those documents. They also, Judge, as it goes later, the defense will tie into other exhibits as I'm getting into that the Government's offered for one reason or the other, and they're definitely relevant as the Court -- Mr. Pickard's testimony will indicate, and as Mr. Pickard's information has been provided to you previously for the appearance of this witness. That's why I didn't mark a and b.

MR. HOUGH: At that point possibly they-- the Court would make a finding that they were relevant and not in violation of Rule 403.

MR. RORK: Judge, 5549 (sic) has been identified and admitted into evidence by this witness as a videotape of the Marquardt

occurrence, which was the initial contact by Mr. Pickard. The witness also indicated there were subsequent contact and communications and information received. He's identified those as an appearing similar in nature to the items received by Mr. Pickard after his forwarding of the videotape and other information.

MR. HOUGH: Judge, the videotape is self-authenticating, those documents are not. Those are hearsay documents. We don't know--we cannot say for certain who authored those documents. All we can say for certain, based upon this foundation, is that they may have been similar to some document that Mr. Pickard sent this witness sometime back in 1995 or thereabouts, but this witness cannot tell us for sure that that's correct.

THE COURT: I think I just asked where-- where did the original documents come from, do we know?

MR. RORK: Those documents there,

Judge, came from Mr. Pickard and Mr. Marquardt

to Mr. Pickard. They were sent by Mr. Pickard,

as the witness indicated, to him. Copies of

those were sent to Mr. Ely at his office.

1	MR. HOUGH: Your Honor, with all due
2	respect, the only thing we know for sure about
3	those documents is that they were seized out of
4	Planet Self-Storage and that this witness at
5	some point in time, around '95 or thereabouts,
6	saw some documents provided to him by Mr.
7	Pickard that may have been similar to those
8	documents. But those certainly cannot be said
9	to be anything that this witness actually saw,
10	because those documents were taken out of Mr.
11	Pickard's locker in Somerville, Massachusetts,
12	at Planet Self-Storage.
13	MR. RORK: Judge, he's indicated he
14	received photocopies of the documents, not the
15	originals. And that those documents appear to
16	be consistent with the photocopies he received
17	based on the typing and spacing.
18	THE COURT: That is very remote,
19	though.
20	MR. RORK: I understand, Judge, but
21	I'm
22	THE COURT: I will just take these
23	under advisement and will not admit them at
24	this time until I find out more about them.
25	MR. RORK: Do you want to keep 50a

1 and b with them? That's the ones that go with 2 those documents that are not identified as--3 Well, not necessarily. THE COURT: 4 We don't have those identified at all. 5 MR. RORK: Well, but they're 6 identified as not being ones he's reviewed, 7 just so that they'll be along with the record. 8 THE COURT: Okay. We can hold them 9 then. 10 DIRECT EXAMINATION 11 BY MR. RORK: (Continued) 12 Do you recall, after receipt of various Q. 13 documents that you've just indicated that were 14 similar in nature of those you've identified, 15 further conversation with Mr. Pickard relative 16 to Mr. Marquardt and the research Mr. Pickard 17 was undertaking with Mr. Marquardt? 18 Α. No. 19 Do you recall a point in time when Mr. Pickard Q. 20 related to you by e-mail or by telephone 21 information that -- that he understood that the 22 lab-- major portion of Mr. Marquardt's lab 23 equipment was still buried somewhere safe in 24 the State of Kansas? 25 Α. I don't recall him saying that it was buried.

1 I remember him making some comment that the 2 major portion of the lab was still secreted 3 here in Kansas. My impression has been that it 4 was at a mini storage or some kind of a storage 5 That would have come on the heels of facility. 6 receiving whatever documentation that Mr. 7 Pickard had represented come from Marquardt. 8 And do you recall -- and when -- being advised by Q. Mr. Pickard that the information he had dealt 9 10 with some of the lab equipment still being 11 secreted somewhere in Kansas, whether or not 12 you made any inquiry of him to-- if he 13 discovered those items, to let you know or keep 14 you posted, along those lines? I-- I don't recall. 15 Α. 16 Do you recall when Mr. Pickard provided you Q. 17 information concerning Mr. Marquardt and the 18 laboratory equipment, any -- you gave Mr. 19 Pickard information specifically stating that 20 the majority of Mr. Marquardt's lab equipment 21 had not been seized in the Kansas raid? 22 No, I don't recall saying that. I didn't have Α. 23 that much intimate knowledge of that particular 24 investigation. 25 Q. Do you recall a point in time when Mr. Pickard

1 advised you of writings to Mr. Marquardt, that you then attended some conference where you had 2 3 contact with the lead agent in the Marquardt 4 case and discussions may have been had about 5 Mr. Pickard's contact with Mr. Marquardt? 6 There was -- again, there was some information Α. provided, I believe it was shortly after 8 receiving the documents that he said came from 9 Mr. Marquardt, that I was at a clandestine 10 laboratory investigators meeting in Las Vegas. 11 I was performing training for agents doing 12 synthesis throughout the day, letting them make 13 methamphetamine for training purposes. And I 14 had heard that one of the agents involved in 15 that particular case was at the meeting. And I 16 was going to try to corner him that night 17 when-- during social hour and just discuss it 18 and maybe pass it on to see what, if anything, 19 he knew about it, whether there was any 20 validity to it or not. 21 As it turned out, the agent had come in 22 the day before, taught that day and left late 23 that afternoon and I never -- never saw him. 24 never followed up on it any further. 25 Q. Do you ever recall communicating to Mr. Pickard that some of the information he had provided you had been discussed with or talked about between you and the lead agent?

- A. I don't even know who the lead agent was on it.

 The majority of my information regarding the

 Marquardt case came off that Day One tape.

 Other than what was on that Day One tape in a

 couple of casual conversations with our chemist

 in Chicago, who were at that particular site, I

 don't know who the agent was who ran the

 operation, I don't know the bodies involved or

 the circumstances.
- Q. But when you said you had heard at the convention in Las Vegas that one of the agents that had been involved in that case, you're referring to while you were in Las Vegas you heard that one of the agents who had been involved in the Marquardt case was at that same seminar?
- A. It was either an agent involved in the case or it was the agent's supervisor, I don't recall which. Someone related to that case was there.
- Q. Do you recall after the receipt of material from Mr. Pickard to you, represented by Mr. Pickard to be contact with Mr. Marquardt, Mr.

Pickard advising you that he had put a variety of these materials together and was going to put a-- a-- use them in a presentation that Mr. Pickard was going to put on?

- A. I-- I don't know about a-- a presentation. I do recall there was interest in Mr. Pickard publishing that particular information and the synthetic information that he had obtained in our clan lab chemist or our CLIC journal, and that he was willing to basically go and talk wherever anybody would want to listen to him, do a presentation on it.
- Q. And in relation to Mr. Pickard presenting the paper or some type of material to the CLIC journal, that would be the journal you were talking about earlier that was put out to the people that it's put out to. Correct?
- A. Yes.

- Q. And do you recall advising Mr. Pickard to go ahead and— he could submit whatever he wanted to submit and it would be up to the editorial board to determine whether or not anything would be published?
- A. That's correct. I advised him that if he had something he wanted to write up, to write it

1 up, submit it, it would go out to a peer review 2 board of other chemists within the organization 3 to look at it regarding merit. 4 Q. And during the course of these conversations 5 with Mr. Pickard, do you recall him providing 6 you further information regarding his gathering 7 of data from Mr. Marquardt, other than what 8 you've testified? 9 MR. HOUGH: Judge, we'll object to 10 the leading questions. 11 THE COURT: Well, we've had a lot of 12 them in this case. Please try to make your 13 questions less leading. 14 MR. RORK: Judge, I understand. He's 15 a DEA agent -- a DEA chemist, Your Honor, and 16 works for the Government. And in that regard, 17 usually there's some latitude allowed in those 18 types of questions, so that's why I've been 19 using that. 20 MR. HOUGH: Judge, this is not a 21 hostile witness, to my knowledge. 22 MR. RORK: Judge, I never said he was 23 hostile, I said he was a Government witness, 24 Judge, there's a difference. 25 MR. HOUGH: Judge, that doesn't make

it impossible for somebody to ask him appropriate questions just because he's employed by the Government.

MR. RORK: Judge, I heard what you indicated to me to say.

- Q. (BY MR. RORK) With respect to the lab equipment that Mr. Pickard represented to you that Mr. Marquardt said was secreted in Kansas, as you've testified, do you recall any conversations by Mr. Pickard relative to Mr. Pickard stating if you knew whether or not this would be a sting operation by any Government agency?
- A. No, there was only one mention of this secreted lab equipment and, again, that was made to me after I had received those documents. And that I recall, there was no further discussion of it and he offered no more information, such as a location or parameters of where this thing might be.
- Q. Do you recall in the fentanyl conversations that continued with Mr. Pickard whether or not he ever asked you about the submission of samples for testing of various substances believed to contain fentanyl?

NORA LYON & ASSOCIATES, INC. 1515 S.W. Topeka Blvd., Topeka, KS 66612 Phone: (785) 232-2545 FAX: (785) 232-2720

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Α. To my recollection, we only really had one discussion about fentanyl and fentanyl labs, and that was on that initial phone call when he contacted me after I had advised Doctor Shulgin it would be okay. I do remember him interested in collecting some types of samples for analytical examination relative to some project that he thought he wanted to do or was thinking about doing, but I-- I don't recall offhand if those are specifically fentanyl. You just don't see that much fentanyl, and I would think to make a project out of fentanyl, there's not a lot of fentanyl floating around, it would be a pretty difficult project to put forward. With respect to any discussions of samples, do Q.

- Q. With respect to any discussions of samples, do you recall at any time indicating to Mr.

 Pickard whether or not he should submit those to a private lab in order to avoid any violations of the law?
- A. Well, I-- I think that-- if I recall, there was some intimation that he was looking at working with a project and submitting-- and giving DEA first crack at doing the analysis, because we do typically look at things more thoroughly than the state and local lab on a lot different

level, lower level. We quantitate the purity, we look at by-products and things that a lot of the state and local laboratories don't necessarily have the time to do.

However, there is a mechanism for doing that kind of work and DEA, that I'm aware of, certainly doesn't accept samples from private parties. If there is a situation like that, I'm sure there would be all kinds of attorneys involved and memorandums of understanding and—and things like that to require those kinds of samples. And that's out of my league, I'm a bench chemist, I'm not an administrator, so—

- Q. But do you recall making any suggestions of private labs that were licensed to make any analytical samples?
- A. Yes. I believe I indicated that if he was interested in a lab which might be worthwhile to check on was a laboratory, I believe it was in Philadelphia, called National Medical Services. There is an individual who worked there who was a member of our clandestine laboratory investigation group who I knew who I felt did a reasonable job, was a reasonable chemist, reasonably skilled chemist. His name

was Jason Freed, F-R-E-E-D.

1.5

- Q. Do you recall during the time that you were doing the Las Vegas hands-on meth synthesis for the agents any contact with Mr. Pickard by telephone around that period dealing with Russia and the fentanyl situation in Russia?
- A. I-- I remember conversations with him regarding fentanyl in Russia, but I couldn't put it in a time frame for you.
- Q. And with respect to the conversations of fentanyl in Russia, what do you recall about those?
- A. Again, the-- the primary conversation regarding the fentanyl was this first telephone conversation that we had. I indicated there were several seizures of fentanyl labs in the former Soviet Union, I provided Mr. Pickard with the name of a chemist in the Government laboratory in Moscow, who was also a member of our CLIC group named Vladimir Sorokin.
- Q. And that word, V-L-A-D-I-M-I-R for the first name?
- A. I believe so.
- O. And S-O-R-O-K-I-N for the second name?
- 25 A. That's correct. I had had contact with Doctor

Sorokin, he had made submissions to our journal. He was essentially an honorary member of our association in that the yearly dues for our group was more than the man made in a month or two. So we allowed him to be a member on the stipulation that he provided material, information about the drug scene in Russia and we would provide him with copies of our journal.

All I had for Doctor Sorokin was a physical mailing address and a fax number. The fax number, though, did not have any area code or city code or country code. I could never find one and I was never provided with one.

- Q. Do you recall any subsequent contacts with Mr.

 Pickard relating to you follow-up conversations

 Mr. Pickard may have had with his contacts

 regarding this Doctor Sorokin?
- A. All I remember is that it wasn't much maybe more than a day later or so that I got an e-mail from Mr. Pickard saying that here is the country and city and area code for Moscow, that if you're going to fax them, fax them between the hours of eight and five during the day because paper is so precious over there that

they turn their faxes off at night, so there's 1 2 a limited type of window. I-- I believe he indicated that he had 3 4 been in contact with Doctor Sorokin, but I 5 don't recall offhand the topics of their 6 discussion or if he even related them to me. 7 During these initial or subsequent discussions, Ο. 8 if any-- I mean that you've had with Mr. 9 Pickard, besides fentanyl, do you recall 10 talking about something known as methcathinone 11 or something like that? 12 Methcathinone, yes, a little bit. Α. 13 0. And what do you recall about the discussions of 14 methcathinone? 15 Mr. Pickard had indicated that he had presented Α. 16 a paper in the spring of 1994 at the California Association of Criminalists meeting in Oakland, 17 18 California, on methcathinone. I told him that 19 I was kind of surprised that they would allow 20 him to do that. 21 And do you recall Mr. Pickard also discussing Q. 22 with you anything dealing with other synthetic 23 drugs? Do you know, when-- whenever he would call, he 24 Α. 25 would bounce around on so many different

topics. I-- I don't recall. I know that at one point, I think it was probably in our last phone call, he was prodding me about what I thought the future of synthetic illicit substances might be. I know that we had a little bit of a discussion about heroin. So I-- I probably-- probably the only one I really ever recall is heroin after that.

- Q. Do you recall whether or not Mr. Pickard ever discussed with you any proposed contacts Mr. Pickard was going to have with the DEA involving an Afghan national?
- A. His involvement with an Afghan national?
- Q. Yes.

- A. Not-- not that I recall. He-- anytime he would call, he would just drop names left and right that he had just briefed our administrator and just briefed our SAC in the Boston area and was going to do this and was going to do that. And I kind of turn off to people when they start dropping names.
- Q. Do you recall in the conversations with Mr.

 Pickard or any e-mails discussions between you and he-- (reporter interruptions). Do you recall any discussions with Mr. Pickard or

e-mails having any conversations dealing with precursor tracking systems or used as a source of drug intervention?

A. I remember him mentioning that he had spoke with a colleague of mine named Jerry Massetti, who is a forensic scientist with the California Department of Justice Crime Labs regarding the possibility of tracking chemical cans or cans holding the—the solvent Freon, which is a solvent that was commonly used at that time by the large Mexican national methamphetamine laboratory operators.

I recall one e-mail in which he's-- he said that he was going to follow-up with that Jerry or that I should talk to Jerry about, you know, his ideas and I-- I don't know that the beeper technology wasn't something I'm really interested in. Again, I just didn't really care.

- Q. Do you recall any discussions with Mr. Pickard dealing with the Russian MVD?
- A. No.
- Q. Do you know what the Russian MVD is?
- 24 A. No.

Q. Do you recall any discussions with Mr. Pickard

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- that had anything to do with the Russian Mafia
 and their drug activities?
 - There-- there was a discussion I believe we Α. had, or I know we had, about the fact that enforcement was concerned about the opening of the former Soviet block, because it is a rather rich petrochemical area and they have a lot of resources. And, unfortunately, the company-or the country is so poor that they were very motivated by hard currency, that it wouldn't be difficult for somebody with hard currency to go in there and to obtain chemicals which might not otherwise be available just by the fact that you have hard currency money. And I think there was speculation about whether the Russian Mafia might be behind it. But along those terms is what I remember the Russian Mafia being involved in.
 - Q. Do you know if there was any talk about the Russian Mafia being involved in the fentanyl manufacturing going on in Russia?
 - A. I don't-- I don't recall him saying anything along that line, no.
 - Q. In any of your discussions with Mr. Pickard, do you recall information that may have been

1 provided with respect to the use of ephedrine 2 or pseudoephedrine and any changes in the 3 trends of that with manufacturing of meth? 4 We may have. Α. 5 And would pseudoephedrine and ephedrine be the Q. 6 term-- be classified as something that's known 7 as a precursor? 8 Yes. Α. 9 And as a precursor, pseudoephedrine or Q. 10 ephedrine, what would-- what does that mean in layman's terms? 11 12 Well, ephedrine and pseudoephedrine are Α. 13 essentially one step away from methamphetamine. 14 That's the most popular route, the use of 15 pseudoephedrine at this point in time. 16 Certainly if you could control or regulate 17 those chemicals, they would be very difficult 18 for methamphetamine laboratories to happen. 19 And do you recall any discussions with Mr. Ο. 20 Pickard having to deal with lactose and the 21 binder system in the manufacture of any 22 methamphetamine or products? 23 MR. HOUGH: Judge, we'll object to 24 this methamphetamine testimony, it's 25 irrelevant.

1 MR. RORK: Judge, it has to do with 2 the -- towards the end of the question had to do 3 with the synthesis of drugs, what the 4 Government has alleged has been relevant in the 5 entire case, ability to synthesize drugs and 6 make dangerous. 7 MR. HOUGH: Synthesis of 8 methamphetamine is certainly not relative to 9 this case, Judge. 10 THE COURT: Well, let's find out. 11 you remember anything about that? THE WITNESS: It -- it could have been 12 13 a topic, but I don't specifically remember 14 talking to him about it. 15 (BY MR. RORK) Is there any relationship to Q. 16 something that's known as phenyl proplome --17 propylomonine or something like that. Phenyl--18 phenyl propanolamine tablets and any synthesis 19 of methamphetamine? 20 Not from methamphetamine. Phenyl propanolamine Α. 21 was at one time, starting around 1995 or so, we 22 began to see it show up more in illicit 23 laboratories, methamphetamine labs. 24 Unfortunately, when it's chemically converted 25 in the same manner which the ephedrine or

- pseudoephedrine is, you get amphetamine instead
 of methamphetamine.
 - Q. Are you aware or were you aware that Mr.

 Pickard's policy analysis exercise or his

 thesis while he was at the John F. Kennedy

 School of Government where you mailed-- or knew

 he was at, involved the control of fentanyl,

 MDMA and LSD laboratories in Russia?
 - A. No.

- Q. Do you recall any discussions with Mr. Pickard as to whether or not these policy analysis exercise or thesis he was undertaking at the time had been sponsored by anybody at the State Department?
- A. No.
- Q. Do you recall receiving in around 1997 a copy of any papers Mr. Pickard forwarded to you representing to be his policy analysis exercise or thesis?
- A. I never received any other documents from Mr. Pickard, other than the ones he alleged came from Mr. Marquardt.
- Q. And when you were talking to Mr. Pickard about this Doctor Sorokin, the Russian national forensic chemist, do you recall you contacting

1 the doctor and requesting or asking that Doctor 2 Sorokin send chemical procedures from Russian 3 fentanyl labs to Mr. Pickard? 4 Could you rephrase that again, please? Α. 5 Yeah, I'm trying to read my-- do you recall in 0. 6 the contacts that you indicated earlier, there 7 was a referral of Mr. Pickard to a Doctor 8 Sorokin, and you didn't have any means to call 9 him or the telephone number or something? That's correct. 10 Α. 11 Q. And then Mr. Pickard a short time later 12 provided you a means or a method in how to 13 contact him. But do you recall any -- giving 14 Doctor Sorokin any information or making any 15 requests for the doctor to send to Mr. Pickard 16 the chemical procedures for Russian-- from 17 Russian fentanyl labs? 18 I'm sorry, Mr. Rork. Are you finished with Α. 19 your question? 20 Oh, yes. Q. 21 I'm sorry, I was waiting to see if you were Α. 22 collecting thoughts to add on. I never made 23 any direct requests to Mr. Sorokin. As I said 24 at the time, the only contact I had with him 25 was through the mail, and that would take

I never requested him in any way to act on my behalf or whatever. Any contact or anything he did with Mr. Pickard was up to Mr. Sorokin, it was certainly not at my behest.

- Q. I understand. I phrased the question wrong.

 Do you recall Doctor Sorokin ever contacting you and inquiring about whether or not he should send to Mr. Pickard any information on fentanyl labs in Russia?
- A. No, I-- I don't. Again, the-- the contact with Doctor Sorokin, especially coming from that direction, was very laborious, he couldn't post it within Russia, it would have to come out of country, he didn't have e-mail. It was not a quick means of communication. Anything I got from Doctor Sorokin would usually take upwards to four months from the time it left Moscow until it would hit my desk.
- Q. And do you recall any discussions with Mr. Pickard by Mr. Pickard to you reference seven or eight laboratories of fentanyl manufacturing Mr. Pickard was looking at in Russia?
- A. He was probably looking at a couple, at least maybe three or four, which was information I

1 provided him. That was information which 2 Sorokin had published in our CLIC journal. 3 Again, this was at my initial contact with Mr. 4 Pickard that this information was provided. 5 Do you recall Mr. Pickard ever giving you any Q. 6 information in these conversations concerning 7 Mr. Pickard had something ongoing with the 8 Customs Department involving heroin in 9 Afghanistan? 1.0 Α. No. 11 Let me hand you what's been marked as Exhibit 0. 12 P-106 and ask you if you would take a minute to 13 review that and see if any of those items 14 appear to be familiar to you. You don't have 15 to read it out loud or anything, I would just 16 ask that you read it to yourself and see if any of the items contained therein refresh your 17 18 recollection concerning your contacts with Mr. 19 Pickard. 20 These appear to be copies of e-mails from--Α. 21 well, they all seem to be from me to Mr. Pickard, I don't see any of Mr. Pickard's to me 22 23 here, though. 24 Q. And I don't know any -- anything about

computers, but I-- I've been advised that there

may be indications on there where there are arrows and arrows might be a question and then a non-arrow might be a response, if that assists you in your questions, I'm not sure.

- A. The arrows typically indicate that that is material from an e-mail which you're replying to. And this is material that, for example, Mr. Pickard would have had in his e-mail. However, unlike a lot of people, I edit my responses so that I cut out all the superfluous material. And if there's a question about one thing, I will leave that particular comment in so that they know what I'm responding to. So I'm sure there's a lot more in here rather than-- from him to me.
- Q. And even though there may be a lot more in there from him to you, are you aware that at the storage locker in Boston where the Exhibit 549 of the Government was presented and these other items I've handed you, we can only print out evidently what can be printed out from the copies given to us. And in reviewing that docket, P-106, do you know whether or not in reviewing those items in there, does it appear to be e-mails and replies from you to Mr.

1 Pickard and Mr. Pickard's e-mails or replies to you or what does it appear?

- Well, as I said, these are all e-mails from me Α. to Mr. Pickard. It doesn't show his side of what sparked the conversation, unless I'm directly responding to a particular piece of-of his message. All of these e-mail messages that I received from him and back and forth, they were deleted and I got rid of them, you know, shortly after I read them and had any use for them. I certainly didn't have any reason whatsoever to-- to save copies.
- I understand. Q.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Knowing that, I can't validate these as -- as Α. being e-mails from me, because it is pretty easy to-- to doctor these.
- Notwithstanding that fact, does there appear to Ο. be dates and time periods contained on either the beginning to the end-- and these are a tape the Government gave me, so does there-- or a Does there appear to be on that piece of paper printout any dates that correspond to the times of forwarding of any e-mails that would assist you in refreshing your recollection regarding any conversations you had with Mr.